Ondansetron Kalceks 2 mg/ ml Norge - norsk - Statens legemiddelverk

ondansetron kalceks 2 mg/ ml

as kalceks - ondansetronhydrokloriddihydrat - injeksjons-/infusjonsvæske, oppløsning - 2 mg/ ml

Tibsovo Den europeiske union - norsk - EMA (European Medicines Agency)

tibsovo

les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - antineoplastiske midler - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.

Adempas 0.5 mg Norge - norsk - Statens legemiddelverk

adempas 0.5 mg

abacus medicine a/s - riociguat - tablett, filmdrasjert - 0.5 mg

Adempas 1 mg Norge - norsk - Statens legemiddelverk

adempas 1 mg

abacus medicine a/s - riociguat - tablett, filmdrasjert - 1 mg

Adempas 1.5 mg Norge - norsk - Statens legemiddelverk

adempas 1.5 mg

abacus medicine a/s - riociguat - tablett, filmdrasjert - 1.5 mg

Adempas 2 mg Norge - norsk - Statens legemiddelverk

adempas 2 mg

abacus medicine a/s - riociguat - tablett, filmdrasjert - 2 mg

Adempas 2.5 mg Norge - norsk - Statens legemiddelverk

adempas 2.5 mg

abacus medicine a/s - riociguat - tablett, filmdrasjert - 2.5 mg